MARC Record from marc_nuls

LEADER: 04315cam 2200445 i 4500
001 9925186504401661
005 20150320064741.2
008 130926s2014 nyua 000 0 eng
010 $a 2013038907
019 $a857214743$a864085326$a871044483$a879769199
020 $a9780071800532 (hbk. : alk. paper)
020 $a0071800530 (hbk. : alk. paper)
035 $a99962021860
035 $a(OCoLC)859253298$z(OCoLC)857214743$z(OCoLC)864085326$z(OCoLC)871044483$z(OCoLC)879769199
035 $a(OCoLC)ocn859253298
040 $aDNLM/DLC$beng$erda$cDLC$dNLM$dIMN$dYUS$dUKMGB$dYDXCP$dBTCTA$dBDX$dVAM$dOCLCF$dCDX$dJXY$dCUD
042 $apcc
050 00 $aRM263$b.P56 2014
082 00 $a615.5/8$223
130 0 $aPharmacotherapy (New York)
245 10 $aPharmacotherapy :$ba pathophysiologic approach /$cJoseph T. DiPiro, PharmD, FCCP, Executive Dean and Professor, South Carolina College of Pharmacy, University of South Carolina and Medical University of South Carolina, Charleston and Columbia, South Carolina, Robert L. Talbert,PharmD, FCCP, BCPS, FAHA, Professor, Pharmacotherpy Division, College of Pharmacy, University of Texas at Austin, Professor, Department of Medicine, School of Medicine, University of Texas Health Science Center at San Antonio, Texas, Gary C. Yee, PharmD, FCCP, BCOP, Professor and Associate Dean, Department of Pharmacy Practice, College of Pharmancy, University of Nebraska Medical Center, Richmond, Virginia, Gary R. Matzke, FCP, FCCP, FASN, FNAP, Professor and Driector, Pharmacy Practice Transformation Initative and Founding, Director, ACCP/ASHP/VCU Congressional Health Care Policy fellow Program, Department of Pharmacotherpy and Outcome Science, School of Pharmacy, Virinia Commonwealth University, Richmond, Virginia, Barbara G. Wells, FCCP, FASHP, Dean Emeritus and Professor Emeritus, Department of Pharmacy Practice, University of Mississippi, School of Pharmacy, Oxford, Mississippi, L. Michael Posey, BSPharm, MA, Associate Vice President, Periodicals Department, American Pharmacists Association, Washington, District of Columbia .
250 $a9th edition.
264 1 $aNew York :$bMcGraw-Hill Education,$c2014.
300 $axxxviii, 2586 pages :$bcolor illustrated ;$c28 cm.
336 $atext$2rdacontent
337 $aunmediated$2rdamedia
338 $avolume$2rdacarrier
504 $aIncludes bibliographical references and index.
505 00 $gCh. 1.$tEnzyme structure and function /$rEdward A. Meighen --$gCh. 2.$tMechanisms /$rBruce A. Palfey --$tCytochrome P450 example /$rW. Edward Lindup and Neil R. Kitteringham --$tCarbonic anhydrase example /$rClaudiu T. Supuran, Andrea Scozzafava and Angela Casini --$tProteases example /$rAndre J. Niestroj and Hans-Ulrich Demuth --$gCh. 3.$tKinetics /$rIrene Lee and Anthony J. Berdis --$gCh. 4.$tEnzyme inhibitors /$rJure Stojan --$gCh. 5.$tDevelopment of enzyme inhibitors as drugs /$rH. John Smith and Claire Simons --$tEnzyme inhibitor examples for the treatment of breast cancer /$rL. W. Lawrence Woo --$tEnzyme inhibitor examples for the treatment of prostate tumor /$rSamer Haidar and Rolf W. Hartmann --$tThrombin inhibitor examples /$rTorsten Steinmetzer --$tHIV-1 protease drug development examples /$rPaul J. Ala and Chong-Hwan Chang --$tMetalloproteinase-collagenase inhibitor examples /$rClaudiu T. Supuran and Andrea Scozzafava.
520 1 $a"Focusing on the development of enzyme inhibitors as therapeutic drugs, Enzymes and Their Inhibition: Drug Development provides a concise overview of the chemistry of major types of enzymes and their inhibitors. The opening chapters introduce the structure, substrates, kinetics, and mechanisms of enzymes. Subsequent chapters discuss the different types of enzyme inhibitors and the principles involved in developing them into effective drugs."--BOOK JACKET.
650 0 $aChemotherapy.
650 0 $aPhysiology, Pathological.
700 1 $aDiPiro, Joseph T.,$eeditor of compilation.
700 1 $aTalbert, Robert L.,$eeditor of compilation.
700 1 $aYee, Gary C.,$eeditor of compilation.
700 1 $aMatzke, Gary R.,$eeditor of compilation.
700 1 $aWells, Barbara G.,$eeditor of compilation.
700 1 $aPosey, L. Michael,$eeditor of compilation.
947 $hCIRCSTACKS$r31786102993844
980 $a99962021860